Procysbi
What Procysbi is used for
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Procysbi
- Active substance
- mercaptamine
- Disease area
- Cystinosis
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AA04
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A
- Authorised in the EU since
- 2013
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Procysbi used for?
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
What is the active substance in Procysbi?
Procysbi contains mercaptamine.
Who makes Procysbi?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU